US Stock Market Move | Phase 1 trial data for SENTI-202 shows positive results. Senti Biosciences (SNTI.US) opened with a more than 7% increase.
On Tuesday, Senti Biosciences (SNTI.US) opened up more than 7%, trading at $2.54.
On Tuesday, Senti Biosciences (SNTI.US) opened with a gain of over 7%, reaching $2.54. In terms of news, Senti Bio reported updated Phase 1 data for SENTI-202 in R/R AML, showing a 50% overall response rate (ORR), 42% complete response/partial hematological response (CR/CRh), with most patients achieving durable response with minimal residual disease negativity (MRD-negative), and receiving RMAT support to advance to pivotal studies.
Related Articles
US Stock Market Move | Stock prices continued to fall, with Broadcom Inc. (AVGO.US) dropping over 4%, and its high growth performance being questioned.
US Stock Market Move | Planned $7 billion acquisition of cybersecurity company Armis ServiceNow (NOW.US) leads to a drop of over 10%
US Stock Market Move | Hot Chinese concept stocks collectively fell, Alibaba Group Holding Limited Sponsored ADR (BABA.US) fell more than 3%.
US Stock Market Move | Stock prices continued to fall, with Broadcom Inc. (AVGO.US) dropping over 4%, and its high growth performance being questioned.
US Stock Market Move | Planned $7 billion acquisition of cybersecurity company Armis ServiceNow (NOW.US) leads to a drop of over 10%
US Stock Market Move | Hot Chinese concept stocks collectively fell, Alibaba Group Holding Limited Sponsored ADR (BABA.US) fell more than 3%.
RECOMMEND
Valued At $10 Trillion, The Largest IPO In History Is Coming As SpaceX Announces Listing Plan
12/12/2025
Five Imperatives And Eight Tasks: Central Meeting Specifies Next Year’s Economic Work, Highlights Identified
12/12/2025
Over 100 New Listings In Hong Kong This Year As Total Fundraising Tops HKD 270 Billion, Eighteen “A+H” Dual Listings
12/12/2025
